Shanghai, China, August 5, 2021 - Insilico Medicine, an industry leader in artificial intelligence for drug discovery, and Usynova announced to reach strategic cooperation.

The agreement outlines a constructive framework where the two parties will combine the advantages of Insilico Medicine’s end-to-end AI-powered drug discovery platform with Usynova’s experience in the small molecule innovative drug development to accelerate the development of small molecule innovative drugs from the aspects of target screening, molecular design, compound synthesis, with a view to jointly addressing significant unmet medical needs and tackling novel and challenging targets in cancer and autoimmune diseases.

Usynova is an innovative enterprise on drug R&D, the founding team members of which come from multinational pharmaceutical enterprises and domestic CRO leading companies and possess rich experience in drug R&D.  Focusing on the two major areas of autoimmune diseases and cancer, the company has built platforms for small molecule chemical drugs and biomacromolecule drugs, developed several pipeline products at different R&D stages, and carried out two clinical trials.  The cooperation between the two parties will accelerate the introduction of first-in-class and best-in-class small molecule innovative drugs to patients worldwide.  Insilico Medicine is a global leader in AI-powered drug discovery companies. Since 2014, Insilico Medicine developed the AI-powered drug discovery platform consisting of PandaOmics™ AI-powered novel target discovery engine, Chemistry42™ compound design and generation platform, and InClinico™, which predicts clinical trial outcome.

"Insilico Medicine has unique technical capabilities in target discovery and generative chemistry. We hope that the cooperation between the two parties can effectively improve the efficiency and accuracy of small molecule drug R&D. The combination of innovative drug companies and artificial intelligence (AI) technology platforms will definitely change the traditional model of innovative drug R&D in the future. Especially, the fact that AI technology provides a new solution for discovering preclinical candidates compounds for novel and difficult targets. We are committed to explore an efficient drug R&D path jointly", said Dr. Hu Tao, the co-founder and Chief Executive Officer of Usynova.

“Usynova's innovation focuses on the R&D in the fields of cancer and autoimmune diseases and aiming at meeting unmet medical needs. We are pleased to apply Insilico Medicine's cutting-edge AI technology platform to conduct in-depth explorations on novel target identification and drug development for novel and difficult targets. We are aiming to develop first-in-class drugs for the benefit of the cancer and autoimmune patients worldwide”, said Dr. Peng Shengbin, the co-founder and Chief Scientist of Usynova.

“China is on the path to becoming the source of truly innovative medicines for the world. We are very pleased to contribute to this important trend by partnering with the innovative biotechnology company, Usynova, to discover novel biomedicines utilizing the latest advances in next-generation artificial intelligence", said Dr. Alex Zhavoronkov, the co-founder and Chief Executive Officer of Insilico Medicine.

“We are honored to be a partner with Usynova, who takes the commitment to develop First-in-Class and Best-in-Class drugs. Insilico Medicine will make full use of the advantages of the AI-powered drug discovery platform, accelerate the R&D of small molecule innovative drugs of Usynova from the aspects of target screening, molecular design, compound synthesis, and work together with Usynova to provide subversive and efficient solutions for unmet clinical needs”, said Dr. Ren Feng, the Chief Scientist of Insilico Medicine.